Lexeo Therapeutics (NASDAQ:LXEO) Shares Down 5.5% – Time to Sell?

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) shares were down 5.5% during trading on Monday . The company traded as low as $9.10 and last traded at $9.0790. Approximately 68,974 shares were traded during trading, a decline of 88% from the average daily volume of 598,162 shares. The stock had previously closed at $9.61.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the stock. Wall Street Zen raised shares of Lexeo Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Leerink Partners lifted their price target on shares of Lexeo Therapeutics from $9.00 to $20.00 and gave the stock an “outperform” rating in a report on Tuesday, October 7th. Guggenheim started coverage on shares of Lexeo Therapeutics in a research note on Wednesday, October 15th. They set a “buy” rating and a $30.00 price objective on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Lexeo Therapeutics in a research report on Wednesday, October 8th. Finally, Oppenheimer reaffirmed an “outperform” rating and issued a $20.00 target price on shares of Lexeo Therapeutics in a research note on Wednesday, December 10th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Lexeo Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $19.33.

Lexeo Therapeutics Price Performance

The business’s fifty day moving average is $9.48 and its 200-day moving average is $6.97.

Lexeo Therapeutics (NASDAQ:LXEO) last posted its quarterly earnings results on Wednesday, November 5th. The company reported ($0.33) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.15. As a group, equities analysts anticipate that Lexeo Therapeutics, Inc. will post -3.14 EPS for the current year.

Insider Buying and Selling

In related news, insider Tai Sandi See sold 3,888 shares of Lexeo Therapeutics stock in a transaction on Friday, October 17th. The stock was sold at an average price of $8.94, for a total value of $34,758.72. Following the transaction, the insider owned 65,862 shares in the company, valued at approximately $588,806.28. This trade represents a 5.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Eric Adler sold 3,382 shares of the business’s stock in a transaction dated Friday, October 17th. The shares were sold at an average price of $8.94, for a total value of $30,235.08. Following the sale, the insider directly owned 73,261 shares of the company’s stock, valued at approximately $654,953.34. This trade represents a 4.41% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 24,646 shares of company stock valued at $221,037. 5.30% of the stock is currently owned by company insiders.

Institutional Trading of Lexeo Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Balyasny Asset Management L.P. acquired a new position in shares of Lexeo Therapeutics during the 2nd quarter valued at $16,117,000. Frazier Life Sciences Management L.P. raised its position in Lexeo Therapeutics by 363.1% in the second quarter. Frazier Life Sciences Management L.P. now owns 4,424,725 shares of the company’s stock valued at $17,787,000 after purchasing an additional 3,469,210 shares during the period. Affinity Asset Advisors LLC raised its position in Lexeo Therapeutics by 142.4% in the second quarter. Affinity Asset Advisors LLC now owns 3,589,355 shares of the company’s stock valued at $14,429,000 after purchasing an additional 2,108,474 shares during the period. Vestal Point Capital LP lifted its stake in shares of Lexeo Therapeutics by 184.1% during the second quarter. Vestal Point Capital LP now owns 3,228,161 shares of the company’s stock worth $12,977,000 after purchasing an additional 2,091,912 shares in the last quarter. Finally, ADAR1 Capital Management LLC boosted its position in shares of Lexeo Therapeutics by 955.7% in the third quarter. ADAR1 Capital Management LLC now owns 1,531,953 shares of the company’s stock worth $10,172,000 after buying an additional 1,386,844 shares during the period. Institutional investors and hedge funds own 60.67% of the company’s stock.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.